Relationship between PASI and FDLQI in paediatric psoriasis, and treatments used in daily clinical practice

Australas J Dermatol. 2021 May;62(2):190-194. doi: 10.1111/ajd.13536. Epub 2021 Feb 14.

Abstract

Background/objectives: Psoriasis is a chronic, inflammatory skin disease that affects 0.71% of children. Skin diseases can have a significant impact on quality of life not only for the children affected by psoriasis, but also for their parents and carers. This study aimed to achieve more insight into the quality of life (QOL) of family of paediatric patients with psoriasis, and to investigate whether disease severity scores correlate with Family Dermatology Life Quality Index (FDLQI) scores. In addition, we also observed the treatments used to treat paediatric psoriasis in daily clinical practice.

Methods: Patients with paediatric psoriasis aged 16 and under who visited our outpatient department were included. Baseline Psoriasis Area and Severity Index (PASI) and FDLQI were measured and analysed.

Results: Of 157 patients were included in the study. Median PASI was 4.2 (IQR 2.6-6.9), and the median FDLQI was 12 (IQR 7-17). The correlation coefficient between PASI and FDLQI was 0.44 (P < 0.001). Burden of care was the highest scoring item on the FDLQI, followed by emotional impact. 146 patients were treated with topical therapy with a mean improvement in PASI of 3.92. 19 patients underwent phototherapy, and 19 underwent systemic therapy.

Conclusions: In this largest study to date studying the impact of PASI on FDLQI, disease severity was found to be strongly associated with adverse quality of life of family members of paediatric psoriasis patients.

Keywords: FDLQI; PASI; paediatric; psoriasis.

MeSH terms

  • Australia
  • Child
  • Child, Preschool
  • Dermatologic Agents / therapeutic use
  • Family*
  • Female
  • Humans
  • Infant
  • Male
  • Phototherapy
  • Prospective Studies
  • Psoriasis / complications*
  • Psoriasis / therapy
  • Quality of Life*
  • Severity of Illness Index*

Substances

  • Dermatologic Agents